WO2000066090A1 - Amplification of folate-mediated targeting to tumor cells using nanoparticles - Google Patents

Amplification of folate-mediated targeting to tumor cells using nanoparticles Download PDF

Info

Publication number
WO2000066090A1
WO2000066090A1 PCT/AU2000/000405 AU0000405W WO0066090A1 WO 2000066090 A1 WO2000066090 A1 WO 2000066090A1 AU 0000405 W AU0000405 W AU 0000405W WO 0066090 A1 WO0066090 A1 WO 0066090A1
Authority
WO
WIPO (PCT)
Prior art keywords
complex
nanoparticles
targeting molecule
folate
cross
Prior art date
Application number
PCT/AU2000/000405
Other languages
French (fr)
Inventor
Gregory John Russell-Jones
John Fergus Mcewan
Original Assignee
Biotech Australia Pty Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Australia Pty Limited filed Critical Biotech Australia Pty Limited
Priority to JP2000614976A priority Critical patent/JP2002543110A/en
Priority to CA002372834A priority patent/CA2372834A1/en
Priority to AU40942/00A priority patent/AU4094200A/en
Priority to EP00920285A priority patent/EP1206251A4/en
Publication of WO2000066090A1 publication Critical patent/WO2000066090A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • C08H1/06—Macromolecular products derived from proteins derived from horn, hoofs, hair, skin or leather

Definitions

  • the invention relates to the delivery of drug, peptide and protein pharmaceuticals using the folate-mediated uptake system. More particularly the invention relates to the amplification of drug/pharmaceutical delivery with the folate uptake system using a folate-nanoparticle complex. The invention also relates to processes for preparing the complexes, pharmaceutical compositions containing same, methods of treatment involving the complexes and uses of the complexes in the manufacture of medicaments.
  • Folic acid enters cells either through a carrier protein, termed the reduced folate carrier, or via receptor-mediated endocytosis facilitated by the folate receptor.
  • the folate receptor is significantly over-expressed on a large fraction of human cancer cells including ovarian, breast, lung, endometrial, renal, colon, and cancers of myeloid hematopoietic cells.
  • FR- ⁇ is upregulated in malignant tissues of epithelial origin such as ovarian carcinoma, while FR- ⁇ is overexpressed in malignant tissues of nonepithelial origin. While the FR have been detected in normal tissues involved in the retention and uptake of the vitamin, these tissues are in protected sites and generally not accessible following blood-borne delivery of folate conjugates. Thus there is expression in the choroid plexus, the intestinal brush border apical membrane surface and the proximal tubules of the kidney. In the latter case the receptor probably functions to scavenge excreted folate, and as such would not be accessible to large molecule weight folate complexes.
  • Folate-mediated tumor targeting has been exploited to date for delivery of the following molecules and molecular complexes (i) protein toxins, (ii) low-molecular- eight chemotherapeutic agents, (iii) radio-imaging agents (iv) MRI contrast agents, (v) radiotherapeutic agents, (vi) liposomes with entrapped drugs, (vii) genes, (viii) antisense oligonucleotides, (ix) ribozymes, and (x) immunotherapeutic agents.
  • the dose deliverable is small, i.e. one molecule of drug for each molecule of folate, and that the majority of the folate-drug complexes are very small and as such are excreted in the kidneys and re-absorbed in the proximal tubules, thus leading to undesirable accumulation of folate-drug complexes in the kidney.
  • a complex comprising a nanoparticle, to which is coupled a targeting molecule, said nanoparticle enclosing an active substance, and wherein said targeting molecule (hereinafter termed TM) is folic acid, or an analogue thereof possessing binding activity to the folic acid receptor.
  • TM targeting molecule
  • a process for the production of a nanoparticle complex of the invention which process comprises one or more of the following steps :
  • a medicament which comprises a nanoparticle complex of the invention together with a pharmaceutically acceptable carrier, excipient, diluent and/or adjuvant.
  • a method for the treatment, prophylaxis or amelioration of disease, in particular cancer, in a vertebrate host comprises the administration to said host of a therapeutically effective amount of a nanoparticle complex according to the invention.
  • the present invention provides a method for the treatment, prophylaxis or amelioration of cancer in a vertebrate host by administration of a hormone, drug, prodrug, toxin, cytotoxin, immunogen or DNA analogue, which process comprises the parenteral administration to said host of a therapeutically effective amount of a nanoparticle complex according to the invention.
  • a nanoparticle complex of the invention in the preparation of a medicament for the treatment, prophylaxis or amelioration of disease, preferably cancer.
  • a method of delivering an active substance to a tumor or cancer cell comprising contacting said tumor or cancer cell with a nanoparticle complex comprising a nanoparticle to which is coupled a targeting molecule, said nanoparticle enclosing an active substance, and wherein said targeting molecule is folic acid, or an analogue thereof possessing binding activity for the folic acid receptor.
  • the method of delivering the active substance may be achieved in vivo by administering the nanoparticle complex to a host, preferably a vertebrate host, of said tumor or cancer cell.
  • the nanoparticle complex of the invention contains one or more molecules of an active substance to be delivered, the nanoparticle being coupled to the TM to give a complex capable of amplified delivery of the active substance.
  • Figure 1 represents the biodistribution of control and folate coated IBC A nanoparticles in tumor-bearing mice.
  • the recovery of Folate-coated F127 IBCA nanoparticles is compared to the recovery of a control Folate-PEG-C18 complex from Balb/C mice injected with hybridoma tumor cells.
  • the data is presented as the percentage of recovered injected counts, and shows that the quantity of nanoparticles targeted to the scTumor increased in the presence of the surface folate of the nanoparticle complexes of the invention.
  • the nanoparticle complexes of the present invention have been especially targeted to tumor and cancer cells using folic acid or analogues thereof as the targeting moiety.
  • the drug is able to be released from the nanoparticle to the circulatory or lymphatic drainage system, and most preferably to the target tissue of the host. Whilst it is possible these nanoparticle complexes could be used for oral delivery of the drug to the circulatory or lymphatic drainage system in general, the products of this invention and a co-pending polymer delivery invention (Australian provisional patent application No. PQ0147 entitled "Application of Folate-mediated Targeting to Tumor Cells Using Polymers” filed on 4 May 1999 and incorporated herein in its entirety by reference) preferably relate to targeting the active substances to tumor/cancer cells.
  • nanoparticles Two basic forms of nanoparticles have been developed, nanocapsules (or microcapsules) and nanospheres (or microspheres), for enclosing, holding or containing active substances.
  • nanoparticle refers to a small sphere, capsule or pellet ranging in size typically from 1 nanometer to 100 micrometers in size.
  • the target molecules utilised in the invention are folate molecules or analogues thereof which possess binding activity for the folic acid receptor, and in particular to surface folate receptors on tumor cells.
  • Analogues contemplated herein include, but are not limited to, modification to the ring structure, functional groups or side chains of the folic acid molecule including the additional removal of protecting groups and salts and complexes thereof derived from any source such as being chemically synthesised or identified by screening process such as natural product screening provided that the analogue possesses some binding activity for the folic acid receptor.
  • the active substance to be delivered is preferably a hormone, drug, prodrug, toxin, pharmaceutically active protein, immunogen, or DNA or RNA analogue.
  • a complex between folic acid and a biodegradable nanoparticle in which is trapped a toxin or cytotoxic agent as the active substance is provided.
  • Suitable toxins include, but are not limited to, ricin, abrin, diphtheria toxin, modecin, tetanus toxin, mycotoxins, mellitin, ⁇ -amanitin, pokeweed antiviral protein, riosome inhibiting proteins, especially those of wheat, barley, corn, rye, gelonin and maytansinoid.
  • Suitable cytotoxic agents include, but are not limited to alkylating agents such as chlorambucil, cyclophosphamide, melphalan, cyclopropane; anthracycline antitumor antibiotics such as doxorubicin, daunomycin, adriamycin, mitomycin C, 2-(hydroxymethyl)anthraquinone; antimetabolites such as methotrexate, dichloromethatrexate: cisplatin, carboplatin, and metallopeptides containing platinum, copper, vanadium, iron, cobalt, gold, cadmium, zinc and nickel.
  • alkylating agents such as chlorambucil, cyclophosphamide, melphalan, cyclopropane
  • anthracycline antitumor antibiotics such as doxorubicin, daunomycin, adriamycin, mitomycin C, 2-(hydroxymethyl)anthraquinone
  • agents include DON, thymidine, pentamethylmelamin, dianhydrogalactitol, 5-methyl-THF, anguidine, maytansine, neocarzinostatin, chlorozotocin, AZQ, 2'deoxycoformycin, PALA, AD-32, m- AMSA and misonidazole.
  • Other active substances which may be delivered by the folate nanoparticles of the invention include but are not limited to hormones and bioactive peptides and polypeptides, antibiotics, antipyretics, analgesics and antiinflammatory drugs, expectorants, sedatives, muscle relaxants, antiepileptics, antiulcer drugs, antidepressants, antiallergic drugs, cardiotonic drugs, antiarrythmic agents, vasodilators, antihypertensives, anticoagulants and haemostatic agents as known in the art.
  • hormones and bioactive peptides and polypeptides include but are not limited to hormones and bioactive peptides and polypeptides, antibiotics, antipyretics, analgesics and antiinflammatory drugs, expectorants, sedatives, muscle relaxants, antiepileptics, antiulcer drugs, antidepressants, antiallergic drugs, cardiotonic drugs, antiarrythmic agents, vasodilators, antihypertensives, anticoagulants and ha
  • nanoparticles can be formed by any number of methods, several of which are outlined below: -
  • a compound is dissolved in a liquid in which it is soluble (the solvent) and a second liquid (which is miscible with the first liquid, but in which the compound is not soluble) is added to the solvent. As more of the second liquid is added the compound becomes desolvated.
  • the compound rich phase contains an enriched amount of compound which is dispersed as microdroplets in the compound deficient phase.
  • the coalesced material can be chemically crosslinked by a suitable crosslinking agent to form micro- or nano-particles, such as nanoparticles of gelatin or borine serum albumin (BSA).
  • a suitable crosslinking agent such as nanoparticles of gelatin or borine serum albumin (BSA).
  • Solutions of these proteins are desolvated by the addition of sodium sulfate or ammonium sulfate solutions.
  • a suitable cross-linker such as glutaraldehyde or butanedione.
  • a biodegradable cross-linker could be employed, such as a linker containing a disulf ⁇ de bond, an azo-bond or an esterase cleavable bond.
  • the insoluble phase can be used to coat core particles to form microcapsules.
  • An example would be the precipitation of ethyl cellulose from cyclohexane by the addition of polyethylene.
  • Polymers suitable for the formation of nanoparticles by solvent evaporation include, amongst others, poly-lactic acid, poly-(lactide/co-glycolide), poly- hydroxybutyrate, poly-hydroxyvalerate, poly-(hydroxybutyrate/valerate), ethyl cellulose, dextran, polysaccharides, polyalkylcyanoacrylate, poly-methyl-methacrylate, poly(e- caprolactone) and various combinations and co-polymers of the above.
  • Polymers suitable for the formation of nanoparticles by interfacial precipitation/polymerisation include, amongst others, EUDRAGITTM- poly(N ⁇ ,N ⁇ -L- lysinediylterephthaloyl); polymers formed by the reaction of Lysine hydrochloride and p- phthaloyl dichloride; by the reaction of acryloylated maltodextrin or acryloylated hydroxyethyl starch with ammonium peroxodisulfate and N,N,N',N'- tetramethylethylenediamine.
  • Nanoparticles can also be formed by the polymerisation of various diamines such as ethylene diamine, phenylenediamine, toluene diamine, hexamethylene diamine, or diols such as ethylene diol, bisphenol, resorcinol, catechol, pentanediol, hexanediol, dodecanediol, 1,4-butanediol, with diacid chlorides such as sebacoylchloride and adipoyl chloride, or diisocynates such as hexamethylene diisocyanate using the methods fully described in EPA 85870002.4 and as incorporated herein by reference.
  • diamines such as ethylene diamine, phenylenediamine, toluene diamine, hexamethylene diamine, or diols such as ethylene diol, bisphenol, resorcinol, catechol, pentanediol, he
  • Polymers suitable for the formation of nanoparticles by polymer phase separation include co-poly(vinyl chloride: vinyl alcohol: vinyl acetate), cellulosic polymers, polyvinyl acetate, polyvinyl alcohol, polyvinylchloride, natural and synthetic rubbers, polyacrylates, polystyrene and the like. Methods to synthesize such nanoparticles are fully described in USP 4,166,800 which is incorporated herein by reference.
  • Polymers suitable for the formation of nanoparticles by complex coacervation include, amongst others, mixtures of polyanions, such as gum arabic, alginate, carboxymethyl cellulose, carboxymethyl starch, polystyrene sulfonic acid, polyvinyl sulfonic acid, poly- D-glucuronic acid, poly-pyruvic acid, carrageenan, heparin sulphate, polyphosphate with polycations, such as polylysine, gelatin.
  • polyanions such as gum arabic, alginate, carboxymethyl cellulose, carboxymethyl starch, polystyrene sulfonic acid, polyvinyl sulfonic acid, poly- D-glucuronic acid, poly-pyruvic acid, carrageenan, heparin sulphate, polyphosphate with polycations, such as polylysine, gelatin.
  • Polymers suitable for the formation of nanoparticles by polymer/polymer incompatability include, amongst others, ethyl cellulose, ethylene vinyl acetate polymer, poly(lactide), or poly(vinylidene chloride) mixed with polymers such as polyethylene, silicone, polyisobutylenes or polybutadiene.
  • nanoparticles include, starch, cross-linked albumen, polyacrylamide, cross-linked gelatin and others obvious to those skilled in the art of nano sphere preparation.
  • the cross-linking agent may contain a disulf ⁇ de bond or be cleavable by acid, base or periodate.
  • suitable cross-linking agents include: N-(4- azidophenylthio)phthalimide; 4,4'-dithiobisphenylazide; dithiobis(succinimidylpropionate); dimethyl-3,3'-dithiobispropionimidate.2HCl; 3,3'- dithiobis-(sulfosuccinimidylpropionate); ethyl-4-azidophenyl)-l,3'dithiopropionate; sulfosuccinimidyl-2-(m-azido-o-nitrobenzamido)-ethyl- 1 ,3'-dithiobutyrimidate.HCl; N- succinimidyl-(4-azidophenyl)-l,3'dithiopropionate; sul
  • Suitable linking of the carrier to the nanoparticles may be achieved by reaction of the carrier with a carbodiimide and N-hydroxysuccinimide ( ⁇ HS), and then reacting the ⁇ HS derivative with a suitable functional group on the nanoparticle.
  • ⁇ HS carbodiimide and N-hydroxysuccinimide
  • fluoride refers to the carboxylic acid anion of folic acid and, where not stated, the counter cation may be any suitable cation including pharmaceutically acceptable cations and may also include a proton, i.e. folic acid.
  • the term “folate” may be taken to include reference to analogues of the folate molecule, such as methotrexate, and preferably where the analogue possesses some binding activity for the folic acid receptor.
  • treatment and “prophylaxis” is to be considered in its broadest context. The term “treatment” does not necessarily imply that a host is treated until total recovery.
  • prophylaxis does not necessarily mean that the subject will not eventually contract a disease condition. Accordingly, treatment and prophylaxis include amelioration of the symptoms of a particular condition or preventing or otherwise reducing the risk of developing a particular condition.
  • the term “prophylaxis” may be considered as reducing the severity of onset of a particular condition. “Treatment” may also reduce the severity of an existing condition.
  • the subject of the treatment or prophylaxis is preferably a mammal such as but not limited to human, primate, livestock animal (e.g. sheep, cow, horse, donkey, pig) companion animal (e.g. dog, cat) laboratory test animal (e.g. mouse, rabbit, rat, guinea pig, hamster) captive wild animal (e.g. fox, deer).
  • livestock animal e.g. sheep, cow, horse, donkey, pig
  • companion animal e.g. dog, cat
  • laboratory test animal e.g. mouse, rabbit, rat, guinea pig, hamster
  • captive wild animal e.g. fox, deer
  • the agents herein defined may be coadministered with one or more other compounds or molecules.
  • the nanoparticle complex of the invention may be administered in combination with folate polymer complexes, other chemotherapeutic agents or other ameliorative active substances.
  • administered in combination is meant simultaneous administration in the same formulation or in two different formulations via the same or different routes or sequential administration by the same or different routes.
  • sequential administration is meant a time difference of from seconds, minutes, hours or days between the administration of the formulations.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating such as licithin, by the maintenance of the required particle size in the case of dispersion and by the use of superfactants.
  • the preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimersal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilisation.
  • dispersions are prepared by incorporating the various sterilised active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
  • the active ingredients When the active ingredients are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
  • the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, gels, pastes, viscous colloidal dispersions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 1% by weight of active compound.
  • compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit.
  • the amount of active compound in such therapeutically useful compositions in such that a suitable dosage will be obtained.
  • Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 ⁇ g and 2000 mg of active compound.
  • the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
  • the tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; buffering agents such as sodium bicarbonate to neutralise or buffer stomach acid; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring.
  • a binder such as gum tragacanth, acacia, corn starch or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • buffering agents such as sodium bicarbonate to neutralise or buffer
  • any material may be present as coatings or to otherwise modify the physical form of the dosage unit.
  • tablets, pills, or capsules may be coated with shellac, sugar or both.
  • a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations and formulations.
  • Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired.
  • Administration of the agent in the form of a pharmaceutical composition may be performed by any convenient means.
  • the agent of the pharmaceutical composition is contemplated to exhibit therapeutic activity when administered in an amount which depends on the particular case. Variation depends for example, on the human or animal and the agent chosen. Dosage regimes may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily, weekly, monthly or other suitable time intervals or the dose may be proportionally reduced as indicated by the exigencies of the situation.
  • the agent may be administered in any suitable manner.
  • Routes of administration include, but are not limited to, respiratorally, intratracheally, nasopharyngeally, intravenously, intraperitoneally, subcutaneously, intracranially, intradermally, intramuscularly, intraoccularly, intrathecally, intracereberally, intranasally, infusion, orally, rectally, via IV drip, patch and implant.
  • suitable routes are via injection into vessels which supply the tumour or diseased organs.
  • Peptides may also be installed into cavities for example the pleural or peritoneal cavity or injected directly into tumour tissues.
  • Nanoparticles can be formed by a number of techniques common to those knowledgeable in the art, including :- solvent evaporation, complex coacervation, polymer/polymer incompatibility, gelation, interfacial polymerisation and thermal denaturation.
  • An effective amount of the complex is formulated with a pharmaceutically acceptable carrier, diluent or excipient to provide a medicament for administration to a patient requiring treatment of the conditions outlined in the body of the specification.
  • the formulation is prepared using standard pharmaceutical techniques.
  • any protein can be used as the matrix for entrapping drug via the desolvation technique, however preferred proteins according to the invention include bovine serum albumen (BSA), Ovalbumen (OA) and collagen.
  • BSA bovine serum albumen
  • OA Ovalbumen
  • Nanoparticles were prepared by coacervation of BSA following desolvation, according to the method of Oppenheim (Oppenheim, 1984, Oppenheim et al 1984, 1982), Briefly a 40% w/w ammonium sulphate solution was added dropwise to a solution of 1% BSA containing 0.5% w/w Tween 20 and the turbidity monitored by Klett readings, until the turbidity rose rapidly.
  • the solution was placed in an ultra-turrax and 600 ⁇ l of glutaraldehyde was added to cross-link the nanoparticles.
  • Cross-linking was stopped by the addition of a solution of 12% w/w sodium metabisulfite.
  • the antimitotic 5-fluorouracil was incorporated into the nanoparticle of Example 2 by dissolving 5-fluorouracil at 10 g/100 ml of the BSA/Tween solution. Desolvation and cross-linking was carried out as described in Example 2.
  • Proteinaceous nanoparticles prepared by the method of Example 2 were surface coated with folate molecules by reaction of folate with l-ethyl-3-(3- dimethylaminopropyl)carbodiomide (ED AC) and NHS followed by addition to the preformed nanoparticles.
  • ED AC l-ethyl-3-(3- dimethylaminopropyl)carbodiomide
  • Example 5 Preparation of folate-lipid complexes for hydrophobic insertion into nanoparticles
  • a complex of folate to an hydrophobic moiety which can insert, non-covalently, into the surface of the nanoparticles.
  • Such a molecule is easily added at the time of formation of the nanoparticles.
  • the strength of the hydrophobic association is such that there is only a very slow dissociation of the folate from the nanoparticles under physiological conditions.
  • folate-PEA folate-phosphatidyl ethanolamine
  • Phosphatidylethanolamine 100 mg was dissolved in 2 ml chloroform/methanol (50:50, v/v).
  • Folate 100 mg was added to the mixture.
  • the folate was then cross-linked to the PEA by the addition of 200 mg of the carbodiimide, l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC or ED AC). The reaction was allowed to proceed for 90 minutes prior to the addition of the folate-PEA to nanoparticles.
  • EDC or ED AC l-ethyl-3-(3- dimethylaminopropyl)carbodiimide
  • Covalent complexes can be made between analogues of folate and almost any aliphatic or aromatic chains or amphipathic containing a water soluble head group suitable for conjugation and a lipid soluble tail suitable for hydrophobic association within an hydrophobic environment.
  • any lipid (saturated, unsaturated or polyunsaturated) which has a carboxylic acid head group such as oleic acid, octanoic acid, linoleic acid or glycerophophoric acids may be directly conjugated to an amino-folate derivative using a suitable carbodiimide (EDAC or DCC, for example).
  • any amphiphathic molecule possessing an amino-group may be conjugated directly to carboxy-folate using carbodiimides.
  • Example 6 Preparation of folate-Nanoparticles by solvent evaporation.
  • a) Preparation of folate-PEA- [Polymethylmethacrylate] nanoparticles Polymethylmethacrylate (PMM, Polysciences)(MW 12,000; 500 mg) was dissolved in 2 ml of dichloromethane (DCM). The PMM in DCM was then added dropwise to 20 ml of 0.25%) w/w Polyvinylalcohol (PVA) while homogenizing at 13,500 rpm with a Janke & Kunkel Ultraturrax. After 1 minute, 200 ⁇ l of folate-PEA was added and stirred gently overnight. The pink nanoparticles were then harvested by centrifugation, washed three times with water and lyophilised.
  • PMM dichloromethane
  • PVA Polyvinylalcohol
  • Poly-lactic acid (PLA, Polysciences)(MW 50,000; 500 mg) was dissolved in 3 ml of DCM and then homogenised into 20 ml 1% PVA at 13,500 rpm on Ultraturrax T25 with an S25F probe for 5 minutes. Folate-PEA (400 ⁇ l) was added while the solution was stirred gently. Nanoparticles were harvested as described above.
  • Example 7 Covalent conjugation of folate to nanoparticles with surface carboxyl groups.
  • a general method for the conjugation of folate to the surface of nanoparticles made from polymers with free carboxyl groups is outlined below.
  • the specific example utilises commercially available carboxyl-modified nanoparticles.
  • Polysciences FluoresbriteTM carboxylate Nanoparticles (2.5% Solids Latex) were obtained from Polysciences in sizes of 0.045 ⁇ m, 0.49 ⁇ m, 2.2 ⁇ m and 9.97 ⁇ m.
  • One ml of each of the preparations was washed extensively with distilled water and resuspended in 200 ⁇ l of distilled water.
  • To each preparation was added 1.5 mg aminohexyl folate then 5 mg of ED AC.
  • Each preparation was allowed to react overnight, after which unreacted material was removed by repeated washing with distilled water or by dialysis against distilled water.
  • Preformed PL A nanoparticles (10 mg) were gently suspended in distilled water (350 ⁇ l) by rotation on a rotary shaker for 2 hours. Hydrazine hydrate (10 ⁇ l) was added and the suspension was shaken overnight at room temperature. The spheres were spun down and repeatedly washed with water by re-suspension and centrifugation. The washing procedure was repeated until the supernatant failed to give a positive hydrazine test (purple colour upon reaction with a solution of trinitrobenzenl sulphonate (TNBS); 1 mg/ml). The spheres were washed a further two times and the wet pellet used directly for conjugation to folate.
  • TNBS trinitrobenzenl sulphonate
  • Nanocapsules suitable for biodistribution studies were prepared with ,25 I-insulin as ant internal marker. Briefly, 10 mg insulin was dissolved at lOmg/ml in 0.1 M HC1. An aliquot (I ⁇ l) of ,25 I-insulin was added to the cold insulin, which was mixed with lOO ⁇ l miglyol and vortexed. EtOH (10 ml ) was added to the insulin/miglyol mix and mixed by vortexing. Isobutyl-cyanoacrylate IBCA (100 ⁇ l, Sicomet) was added to the clear solution, which was immediately added to 60 ml 0.25% F-127. After 30 minutes the preparation was split into 2 equal halves.
  • DSAB (40 mg) was dissolved in an equal weight of DMF, to which was added NHS (24 mg, 240 ⁇ l DMF).
  • NHS 24 mg, 240 ⁇ l DMF.
  • DCC Dicyclohexylcarbodiimide, 44mg, 440 ⁇ l, made up fresh
  • the DSAB-NHS-ester was added at 0.32 mg per 2.1 mg nanocapsules, and left to stir overnight. The particles were then dialysed before use in biodistribution studies.
  • folate derivatized IBCA nanoparticles were prepared as described in Example 9. Control nanoparticles were prepared without folate.
  • Balb/C mice were injected subcutaneous, y with 2x10 6 hybridoma tumour cells. Two weeks after tumour injection, the radio-labelled nanoparticles were injected intravenously into the mice. At various time-points the mice were bled from the retro-orbital plexus, euthanased and their tissues removed for determination of radioactivity. Data is presented in Figure 1 as the percentage of injected counts that were injected in the mice.
  • the present invention provides a simple and novel technique for the amplification of the folate uptake system, thus enabling the amplified delivery of a wide range of active agents to tumor and cancer cells in particular.

Abstract

The invention relates to the delivery of drug, peptide and protein pharmaceuticals using the folate-mediated uptake system. More particularly the invention relates to the amplification of drug/pharmaceutical delivery with the folate uptake system using a folate-nanoparticle complex. The invention also relates to processes for preparing the complexes, pharmaceutical compositions containing same, methods of treatment involving the complexes and uses of the complexes in the manufacture of medicaments.

Description

AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS
USING NANOPARTICLES
Technical Field
The invention relates to the delivery of drug, peptide and protein pharmaceuticals using the folate-mediated uptake system. More particularly the invention relates to the amplification of drug/pharmaceutical delivery with the folate uptake system using a folate-nanoparticle complex. The invention also relates to processes for preparing the complexes, pharmaceutical compositions containing same, methods of treatment involving the complexes and uses of the complexes in the manufacture of medicaments.
Background Art
In conventional cancer chemotherapy, in order to obtain a linear increase in killing of cancer cells it is often necessary to increase the amount of cytotoxic drugs present in the system in an exponential fashion. This in turn leads to an undesirable increase in nonspecific cytotoxicity of bistander, healthy cells. Hence it is often necessary to repeatedly deliver a smaller dose of cytotoxin, which inevitably leads to the survival of a small fraction of drug-resistant cells. In an attempt to increase the dose of cytotoxic agent delivered to the tumor cell, specific targeting agents such as monoclonal antibodies to "tumor-specific antigens" have been employed. In many cases the resultant antibody-drug conjugate may be highly immunogenic, and thus lead to an antibody response against the conjugate thereby precluding further use. For this reason small, poorly immunogenic, tumor-specific molecules have been sought as alternatives to antibody molecules. Recently focus has switched to the use of molecules essential for growth to be used as targeting agents. The use of one of these, folic acid, is the subject of the current application. Folic acid enters cells either through a carrier protein, termed the reduced folate carrier, or via receptor-mediated endocytosis facilitated by the folate receptor. The folate receptor is significantly over-expressed on a large fraction of human cancer cells including ovarian, breast, lung, endometrial, renal, colon, and cancers of myeloid hematopoietic cells. There are two folate receptors FR-α, and FR-β. In general FR-α, is upregulated in malignant tissues of epithelial origin such as ovarian carcinoma, while FR-β is overexpressed in malignant tissues of nonepithelial origin. While the FR have been detected in normal tissues involved in the retention and uptake of the vitamin, these tissues are in protected sites and generally not accessible following blood-borne delivery of folate conjugates. Thus there is expression in the choroid plexus, the intestinal brush border apical membrane surface and the proximal tubules of the kidney. In the latter case the receptor probably functions to scavenge excreted folate, and as such would not be accessible to large molecule weight folate complexes. Folate-mediated tumor targeting has been exploited to date for delivery of the following molecules and molecular complexes (i) protein toxins, (ii) low-molecular- eight chemotherapeutic agents, (iii) radio-imaging agents (iv) MRI contrast agents, (v) radiotherapeutic agents, (vi) liposomes with entrapped drugs, (vii) genes, (viii) antisense oligonucleotides, (ix) ribozymes, and (x) immunotherapeutic agents.
Two major limitations to the use of folate to target to tumor cells is that the dose deliverable is small, i.e. one molecule of drug for each molecule of folate, and that the majority of the folate-drug complexes are very small and as such are excreted in the kidneys and re-absorbed in the proximal tubules, thus leading to undesirable accumulation of folate-drug complexes in the kidney.
It is an object of the present invention to overcome or at least alleviate one or more of the above-mentioned disadvantages of the prior art.
Summary of the Invention
Surprisingly it has been found by the present inventors that both of the above-mentioned limitations could be addressed by incorporation of the active substance to be delivered within a nanoparticle, which is coated with folic acid or an analogue thereof. Thus, amplification of drug/pharmaceutical delivery can occur by incorporation of quantities of the active substance within the folate-coated nanoparticle. Accumulation of the folate-drug complexes in the kidneys is also minimised due to the large size of the nanoparticle.
According to a first aspect of the present invention there is provided a complex comprising a nanoparticle, to which is coupled a targeting molecule, said nanoparticle enclosing an active substance, and wherein said targeting molecule (hereinafter termed TM) is folic acid, or an analogue thereof possessing binding activity to the folic acid receptor.
According to a second aspect of the present invention there is provided a process for the production of a nanoparticle complex of the invention, which process comprises one or more of the following steps :
(a) reacting nanoparticles with a TM to form the complex;
(b) chemically modifying a TM to provide at least one functional group capable of forming a chemical linkage and reacting nanoparticles and the modified TM to form the complex;
(c) reacting nanoparticles with at least one cross-linking agent to prepare "activated" nanoparticles which are reacted with a TM to form the complex;
(d) reacting a TM with at least one cross-linking agent and reacting the nanoparticles with the reacted TM to form the complex;
(e) reacting nanoparticles and a TM with at least one cross-linking agent to form the complex;
(f) reacting nanoparticles with at least one cross-linking agent, reacting a TM with at least one cross-linking agent and reacting the reacted nanoparticles and the reacted TM to form the complex; or
(g) reacting a TM with at least one cross-linking agent to prepare an analogue which is reacted with a hydrophobic moiety to form a hydrophobic derivative of the TM; and then incubating the hydrophobic derivative of the TM with a nanoparticle in such a manner that the nanoparticle is coated hydrophobically with the TM. According to a third aspect of the present invention there is provided a medicament which comprises a nanoparticle complex of the invention together with a pharmaceutically acceptable carrier, excipient, diluent and/or adjuvant.
According to a fourth aspect of the present invention there is provided a method for the treatment, prophylaxis or amelioration of disease, in particular cancer, in a vertebrate host which method comprises the administration to said host of a therapeutically effective amount of a nanoparticle complex according to the invention.
According to a fifth aspect the present invention provides a method for the treatment, prophylaxis or amelioration of cancer in a vertebrate host by administration of a hormone, drug, prodrug, toxin, cytotoxin, immunogen or DNA analogue, which process comprises the parenteral administration to said host of a therapeutically effective amount of a nanoparticle complex according to the invention.
According to a sixth aspect of the present invention there is provided the use of a nanoparticle complex of the invention in the preparation of a medicament for the treatment, prophylaxis or amelioration of disease, preferably cancer.
According to a seventh aspect of the present invention there is provided a method of delivering an active substance to a tumor or cancer cell comprising contacting said tumor or cancer cell with a nanoparticle complex comprising a nanoparticle to which is coupled a targeting molecule, said nanoparticle enclosing an active substance, and wherein said targeting molecule is folic acid, or an analogue thereof possessing binding activity for the folic acid receptor. The method of delivering the active substance may be achieved in vivo by administering the nanoparticle complex to a host, preferably a vertebrate host, of said tumor or cancer cell.
The nanoparticle complex of the invention contains one or more molecules of an active substance to be delivered, the nanoparticle being coupled to the TM to give a complex capable of amplified delivery of the active substance. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
Brief Description of the Figure
The present invention will now be described by way of example only and with reference to the figure wherein:
Figure 1 represents the biodistribution of control and folate coated IBC A nanoparticles in tumor-bearing mice. The recovery of Folate-coated F127 IBCA nanoparticles is compared to the recovery of a control Folate-PEG-C18 complex from Balb/C mice injected with hybridoma tumor cells. The data is presented as the percentage of recovered injected counts, and shows that the quantity of nanoparticles targeted to the scTumor increased in the presence of the surface folate of the nanoparticle complexes of the invention.
Detailed Description of the Invention
The nanoparticle complexes of the present invention have been especially targeted to tumor and cancer cells using folic acid or analogues thereof as the targeting moiety. The drug is able to be released from the nanoparticle to the circulatory or lymphatic drainage system, and most preferably to the target tissue of the host. Whilst it is possible these nanoparticle complexes could be used for oral delivery of the drug to the circulatory or lymphatic drainage system in general, the products of this invention and a co-pending polymer delivery invention (Australian provisional patent application No. PQ0147 entitled "Application of Folate-mediated Targeting to Tumor Cells Using Polymers" filed on 4 May 1999 and incorporated herein in its entirety by reference) preferably relate to targeting the active substances to tumor/cancer cells.
Two basic forms of nanoparticles have been developed, nanocapsules (or microcapsules) and nanospheres (or microspheres), for enclosing, holding or containing active substances. The term "nanoparticle" as used throughout the specification refers to a small sphere, capsule or pellet ranging in size typically from 1 nanometer to 100 micrometers in size.
The target molecules utilised in the invention are folate molecules or analogues thereof which possess binding activity for the folic acid receptor, and in particular to surface folate receptors on tumor cells. Analogues contemplated herein include, but are not limited to, modification to the ring structure, functional groups or side chains of the folic acid molecule including the additional removal of protecting groups and salts and complexes thereof derived from any source such as being chemically synthesised or identified by screening process such as natural product screening provided that the analogue possesses some binding activity for the folic acid receptor.
The active substance to be delivered is preferably a hormone, drug, prodrug, toxin, pharmaceutically active protein, immunogen, or DNA or RNA analogue.
In an embodiment of the invention there is provided a complex between folic acid and a biodegradable nanoparticle in which is trapped a toxin or cytotoxic agent as the active substance.
Suitable toxins, according to the invention, include, but are not limited to, ricin, abrin, diphtheria toxin, modecin, tetanus toxin, mycotoxins, mellitin, α-amanitin, pokeweed antiviral protein, riosome inhibiting proteins, especially those of wheat, barley, corn, rye, gelonin and maytansinoid.
Suitable cytotoxic agents, according to the invention, include, but are not limited to alkylating agents such as chlorambucil, cyclophosphamide, melphalan, cyclopropane; anthracycline antitumor antibiotics such as doxorubicin, daunomycin, adriamycin, mitomycin C, 2-(hydroxymethyl)anthraquinone; antimetabolites such as methotrexate, dichloromethatrexate: cisplatin, carboplatin, and metallopeptides containing platinum, copper, vanadium, iron, cobalt, gold, cadmium, zinc and nickel. Other agents include DON, thymidine, pentamethylmelamin, dianhydrogalactitol, 5-methyl-THF, anguidine, maytansine, neocarzinostatin, chlorozotocin, AZQ, 2'deoxycoformycin, PALA, AD-32, m- AMSA and misonidazole.
Other active substances which may be delivered by the folate nanoparticles of the invention include but are not limited to hormones and bioactive peptides and polypeptides, antibiotics, antipyretics, analgesics and antiinflammatory drugs, expectorants, sedatives, muscle relaxants, antiepileptics, antiulcer drugs, antidepressants, antiallergic drugs, cardiotonic drugs, antiarrythmic agents, vasodilators, antihypertensives, anticoagulants and haemostatic agents as known in the art.
In essence the nanoparticles can be formed by any number of methods, several of which are outlined below: -
(i) Solvent Evaporation In which a compound which is soluble in one solvent is dispersed into another miscible solvent and the first solvent is evaporated off. Particles formed in this fashion have been used to administer (parenterally) a number of water insoluble compounds. An example of such a system is the formation of polyalkylcyanoacrylate nanocapsules in which the anticancer agent 5-fluorouracil is entrapped.
(ii) Desolvation
In this method a compound is dissolved in a liquid in which it is soluble (the solvent) and a second liquid (which is miscible with the first liquid, but in which the compound is not soluble) is added to the solvent. As more of the second liquid is added the compound becomes desolvated. During the process of desolvation the compound rich phase (the coacervate) contains an enriched amount of compound which is dispersed as microdroplets in the compound deficient phase. At this stage the coalesced material can be chemically crosslinked by a suitable crosslinking agent to form micro- or nano-particles, such as nanoparticles of gelatin or borine serum albumin (BSA). Solutions of these proteins are desolvated by the addition of sodium sulfate or ammonium sulfate solutions. At the point of desolvation there is an increase in turbidity, at which time the nanoparticles can be formed by the addition of a suitable cross-linker such as glutaraldehyde or butanedione. Alternatively a biodegradable cross-linker could be employed, such as a linker containing a disulfϊde bond, an azo-bond or an esterase cleavable bond.
(iii) Complex coacervation
In this procedure two polyelectrolytes having opposite charge are mixed in an aqueous medium so that a spontaneous liquid/liquid phase separation occurs. The phenomenon is limited to polymers having a suitable ionic charge density and chain length. Typically these nanoparticles are formed by the addition of a polyanion such as gum arabic, alginate, or polyphosphate, to a polycation such as gelatin. Suitable particles are readily formed by the complexation of gelatin and carboxymethyl cellulose. The rate of release of pharmaceutical from such complexes can be controlled by the addition of a suitable cross-linker such as glutaraldehyde or butanedione. Alternatively a biodegradable cross-linker could be employed, such as a linker containing a disulfide bond, an azo-bond or an esterase cleavable bond.
(iv) Polymer/polymer incompatability
This procedure is based upon the observation that two chemically different polymers dissolved in a common solvent are usually incompatible. Thus the mixture will tend to form two phases. The insoluble phase can be used to coat core particles to form microcapsules. An example would be the precipitation of ethyl cellulose from cyclohexane by the addition of polyethylene.
(v) Interfacial polymerisation In this technique, two reactants, each dissolved in a mutually immiscible liquid, diffuse to the interface between the two liquids where they react to form a capsule wall. An example of such capsule formation occurs when a mixture of sebacoyl chloride dissolved in an oil phase is emulsified into an aqueous phase containing ethylenediamine.
Polymers suitable for the formation of nanoparticles by solvent evaporation (in liquid drying) include, amongst others, poly-lactic acid, poly-(lactide/co-glycolide), poly- hydroxybutyrate, poly-hydroxyvalerate, poly-(hydroxybutyrate/valerate), ethyl cellulose, dextran, polysaccharides, polyalkylcyanoacrylate, poly-methyl-methacrylate, poly(e- caprolactone) and various combinations and co-polymers of the above.
Polymers suitable for the formation of nanoparticles by interfacial precipitation/polymerisation include, amongst others, EUDRAGITTM- poly(Nα,Nε-L- lysinediylterephthaloyl); polymers formed by the reaction of Lysine hydrochloride and p- phthaloyl dichloride; by the reaction of acryloylated maltodextrin or acryloylated hydroxyethyl starch with ammonium peroxodisulfate and N,N,N',N'- tetramethylethylenediamine. Nanoparticles can also be formed by the polymerisation of various diamines such as ethylene diamine, phenylenediamine, toluene diamine, hexamethylene diamine, or diols such as ethylene diol, bisphenol, resorcinol, catechol, pentanediol, hexanediol, dodecanediol, 1,4-butanediol, with diacid chlorides such as sebacoylchloride and adipoyl chloride, or diisocynates such as hexamethylene diisocyanate using the methods fully described in EPA 85870002.4 and as incorporated herein by reference.
Polymers suitable for the formation of nanoparticles by polymer phase separation include co-poly(vinyl chloride: vinyl alcohol: vinyl acetate), cellulosic polymers, polyvinyl acetate, polyvinyl alcohol, polyvinylchloride, natural and synthetic rubbers, polyacrylates, polystyrene and the like. Methods to synthesize such nanoparticles are fully described in USP 4,166,800 which is incorporated herein by reference.
Polymers suitable for the formation of nanoparticles by complex coacervation include, amongst others, mixtures of polyanions, such as gum arabic, alginate, carboxymethyl cellulose, carboxymethyl starch, polystyrene sulfonic acid, polyvinyl sulfonic acid, poly- D-glucuronic acid, poly-pyruvic acid, carrageenan, heparin sulphate, polyphosphate with polycations, such as polylysine, gelatin.
Polymers suitable for the formation of nanoparticles by polymer/polymer incompatability include, amongst others, ethyl cellulose, ethylene vinyl acetate polymer, poly(lactide), or poly(vinylidene chloride) mixed with polymers such as polyethylene, silicone, polyisobutylenes or polybutadiene.
Other materials suitable for formation of nanoparticles include, starch, cross-linked albumen, polyacrylamide, cross-linked gelatin and others obvious to those skilled in the art of nano sphere preparation.
The cross-linking agent may contain a disulfϊde bond or be cleavable by acid, base or periodate. Examples of suitable cross-linking agents include: N-(4- azidophenylthio)phthalimide; 4,4'-dithiobisphenylazide; dithiobis(succinimidylpropionate); dimethyl-3,3'-dithiobispropionimidate.2HCl; 3,3'- dithiobis-(sulfosuccinimidylpropionate); ethyl-4-azidophenyl)-l,3'dithiopropionate; sulfosuccinimidyl-2-(m-azido-o-nitrobenzamido)-ethyl- 1 ,3'-dithiobutyrimidate.HCl; N- succinimidyl-(4-azidophenyl)-l,3'dithiopropionate; sulfosuccinimidyl-2-(m-azido-o- nitrobenzamido)-ethyl-l ,3'-dithiopropionate; sulfosuccinimidyl-2-(p-azidosalicylamido)- ethyl- 1 ,3'-dithiopropionate; N-succinimidyl-3-(2-pyridylthio)propionate; sulfosuccinimidyl-(4-azidophenyldithio)-propionate; 2-iminothiolane; disuccinimidyl tartrate; and bis-[2-(succinimidyloxycarbonyloxy)-ethyl]-sulfone.
Suitable linking of the carrier to the nanoparticles may be achieved by reaction of the carrier with a carbodiimide and N-hydroxysuccinimide (ΝHS), and then reacting the ΝHS derivative with a suitable functional group on the nanoparticle.
Reference to the term "folate" as used herein is to be considered in its broadest context and refers to the carboxylic acid anion of folic acid and, where not stated, the counter cation may be any suitable cation including pharmaceutically acceptable cations and may also include a proton, i.e. folic acid. The term "folate" may be taken to include reference to analogues of the folate molecule, such as methotrexate, and preferably where the analogue possesses some binding activity for the folic acid receptor. Reference herein to "treatment" and "prophylaxis" is to be considered in its broadest context. The term "treatment" does not necessarily imply that a host is treated until total recovery. Similarly, "prophylaxis" does not necessarily mean that the subject will not eventually contract a disease condition. Accordingly, treatment and prophylaxis include amelioration of the symptoms of a particular condition or preventing or otherwise reducing the risk of developing a particular condition. The term "prophylaxis" may be considered as reducing the severity of onset of a particular condition. "Treatment" may also reduce the severity of an existing condition.
The subject of the treatment or prophylaxis is preferably a mammal such as but not limited to human, primate, livestock animal (e.g. sheep, cow, horse, donkey, pig) companion animal (e.g. dog, cat) laboratory test animal (e.g. mouse, rabbit, rat, guinea pig, hamster) captive wild animal (e.g. fox, deer). Preferably the mammal is a human or primate. Most preferably the mammal is a human.
It will be understood that those skilled in the art will be able to employ methods commonly known in the art for preparing suitable medicaments in concentrations and presented in forms appropriate to the administration of the folate complexes of the invention, optionally with other active agents as required, in suitable treatment regimes to achieve the desired physiological effects on the vertebrate host to be treated.
In accordance with these methods, the agents herein defined may be coadministered with one or more other compounds or molecules. For example, the nanoparticle complex of the invention may be administered in combination with folate polymer complexes, other chemotherapeutic agents or other ameliorative active substances. By "administered in combination" is meant simultaneous administration in the same formulation or in two different formulations via the same or different routes or sequential administration by the same or different routes. By "sequential" administration is meant a time difference of from seconds, minutes, hours or days between the administration of the formulations. These agents may be administered in any order. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as licithin, by the maintenance of the required particle size in the case of dispersion and by the use of superfactants. The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimersal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilisation. Generally, dispersions are prepared by incorporating the various sterilised active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
When the active ingredients are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, gels, pastes, viscous colloidal dispersions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions in such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 μg and 2000 mg of active compound. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; buffering agents such as sodium bicarbonate to neutralise or buffer stomach acid; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations. Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired.
Administration of the agent in the form of a pharmaceutical composition may be performed by any convenient means. The agent of the pharmaceutical composition is contemplated to exhibit therapeutic activity when administered in an amount which depends on the particular case. Variation depends for example, on the human or animal and the agent chosen. Dosage regimes may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily, weekly, monthly or other suitable time intervals or the dose may be proportionally reduced as indicated by the exigencies of the situation. The agent may be administered in any suitable manner. Routes of administration include, but are not limited to, respiratorally, intratracheally, nasopharyngeally, intravenously, intraperitoneally, subcutaneously, intracranially, intradermally, intramuscularly, intraoccularly, intrathecally, intracereberally, intranasally, infusion, orally, rectally, via IV drip, patch and implant. With respect to intravenous routes, particularly suitable routes are via injection into vessels which supply the tumour or diseased organs. Peptides may also be installed into cavities for example the pleural or peritoneal cavity or injected directly into tumour tissues.
The invention is further described with reference to the following examples which are in no way limiting on the scope of the invention.
Example 1 Preparation of nanoparticles
Nanoparticles can be formed by a number of techniques common to those knowledgeable in the art, including :- solvent evaporation, complex coacervation, polymer/polymer incompatibility, gelation, interfacial polymerisation and thermal denaturation.
An effective amount of the complex is formulated with a pharmaceutically acceptable carrier, diluent or excipient to provide a medicament for administration to a patient requiring treatment of the conditions outlined in the body of the specification. The formulation is prepared using standard pharmaceutical techniques.
It is recognised that a number of factors will affect the determination of an appropriate dosage for a particular host. Such factors include the age, weight, sex, general health and concurrent disease states of the host. The determination of the appropriate dose level for the particular host is performed by standard pharmaceutical techniques.
Example 2 Preparation of nanoparticles by Coacervation.
Almost any protein can be used as the matrix for entrapping drug via the desolvation technique, however preferred proteins according to the invention include bovine serum albumen (BSA), Ovalbumen (OA) and collagen. Nanoparticles were prepared by coacervation of BSA following desolvation, according to the method of Oppenheim (Oppenheim, 1984, Oppenheim et al 1984, 1982), Briefly a 40% w/w ammonium sulphate solution was added dropwise to a solution of 1% BSA containing 0.5% w/w Tween 20 and the turbidity monitored by Klett readings, until the turbidity rose rapidly. At this point (determined by experimentation) the solution was placed in an ultra-turrax and 600 μl of glutaraldehyde was added to cross-link the nanoparticles. Cross-linking was stopped by the addition of a solution of 12% w/w sodium metabisulfite.
Particles were then washed repeatedly with distilled water prior to coupling to the N- hydroxysuccinimide (NHS)-derivative of folic acid
Example 3 Incorporation of 5-fluorouracil
The antimitotic 5-fluorouracil was incorporated into the nanoparticle of Example 2 by dissolving 5-fluorouracil at 10 g/100 ml of the BSA/Tween solution. Desolvation and cross-linking was carried out as described in Example 2.
Example 4 Coupling of folate to nanoparticles
Proteinaceous nanoparticles (prepared by the method of Example 2) were surface coated with folate molecules by reaction of folate with l-ethyl-3-(3- dimethylaminopropyl)carbodiomide (ED AC) and NHS followed by addition to the preformed nanoparticles.
Example 5 Preparation of folate-lipid complexes for hydrophobic insertion into nanoparticles In order to link folate to the surface of nanoparticles which have no readily available chemical groups suitable for chemical conjugation, it is possible to prepare a complex of folate to an hydrophobic moiety which can insert, non-covalently, into the surface of the nanoparticles. Such a molecule is easily added at the time of formation of the nanoparticles. The strength of the hydrophobic association is such that there is only a very slow dissociation of the folate from the nanoparticles under physiological conditions. a) Preparation of folate-phosphatidyl ethanolamine (folate-PEA) Phosphatidylethanolamine (100 mg) was dissolved in 2 ml chloroform/methanol (50:50, v/v). Folate (100 mg) was added to the mixture. The folate was then cross-linked to the PEA by the addition of 200 mg of the carbodiimide, l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC or ED AC). The reaction was allowed to proceed for 90 minutes prior to the addition of the folate-PEA to nanoparticles. b) Preparation of other complexes between folate and an hydrophobic moiety. Covalent complexes can be made between analogues of folate and almost any aliphatic or aromatic chains or amphipathic containing a water soluble head group suitable for conjugation and a lipid soluble tail suitable for hydrophobic association within an hydrophobic environment. Thus, any lipid (saturated, unsaturated or polyunsaturated) which has a carboxylic acid head group, such as oleic acid, octanoic acid, linoleic acid or glycerophophoric acids may be directly conjugated to an amino-folate derivative using a suitable carbodiimide (EDAC or DCC, for example). Similarly any amphiphathic molecule possessing an amino-group (amino-hexane, amino-decane, amino-dodecane, phosphatidyl-ethanolamine, may be conjugated directly to carboxy-folate using carbodiimides.
Example 6 Preparation of folate-Nanoparticles by solvent evaporation. a) Preparation of folate-PEA- [Polymethylmethacrylate] nanoparticles Polymethylmethacrylate (PMM, Polysciences)(MW 12,000; 500 mg) was dissolved in 2 ml of dichloromethane (DCM). The PMM in DCM was then added dropwise to 20 ml of 0.25%) w/w Polyvinylalcohol (PVA) while homogenizing at 13,500 rpm with a Janke & Kunkel Ultraturrax. After 1 minute, 200 μl of folate-PEA was added and stirred gently overnight. The pink nanoparticles were then harvested by centrifugation, washed three times with water and lyophilised.
b) Preparation of folate-[PEA-Poly-lactic acid] nanoparticles.
Poly-lactic acid (PLA, Polysciences)(MW 50,000; 500 mg) was dissolved in 3 ml of DCM and then homogenised into 20 ml 1% PVA at 13,500 rpm on Ultraturrax T25 with an S25F probe for 5 minutes. Folate-PEA (400 μl) was added while the solution was stirred gently. Nanoparticles were harvested as described above.
c) Preparation of folate-PEA- [Poly-Hydroxy-butyrate/valerate] nanoparticles Poly-hydroxy-butyrate/valerate (9% valerate) (ICI; 500 mg) was dissolved in 5 ml of DCM and homogenised into 20 ml 1% PVA at 13,500 rpm on Ultraturrax T25 with an S25F probe for 5 minutes. Folate-PEA (400 μl) was added and the spheres processed as described in Example 8b.
Example 7 Covalent conjugation of folate to nanoparticles with surface carboxyl groups.
A general method for the conjugation of folate to the surface of nanoparticles made from polymers with free carboxyl groups is outlined below. The specific example utilises commercially available carboxyl-modified nanoparticles. Polysciences FluoresbriteTM carboxylate Nanoparticles (2.5% Solids Latex) were obtained from Polysciences in sizes of 0.045 μm, 0.49 μm, 2.2 μm and 9.97 μm. One ml of each of the preparations was washed extensively with distilled water and resuspended in 200 μl of distilled water. To each preparation was added 1.5 mg aminohexyl folate then 5 mg of ED AC. Each preparation was allowed to react overnight, after which unreacted material was removed by repeated washing with distilled water or by dialysis against distilled water.
Example 8 Surface derivatization of nanoparticle
Many polymers used in the preparation of nanoparticles by solvent evaporation do not contain functional groups for direct conjugation to folate or its functionalised analogues, however it is possible to modify the surface of the preformed nanoparticles to introduce functional groups suitable for conjugation to folate. a) Surface derivatization of polylactic acid (PL A) nanoparticles
Preformed PL A nanoparticles (10 mg) were gently suspended in distilled water (350 μl) by rotation on a rotary shaker for 2 hours. Hydrazine hydrate (10 μl) was added and the suspension was shaken overnight at room temperature. The spheres were spun down and repeatedly washed with water by re-suspension and centrifugation. The washing procedure was repeated until the supernatant failed to give a positive hydrazine test (purple colour upon reaction with a solution of trinitrobenzenl sulphonate (TNBS); 1 mg/ml). The spheres were washed a further two times and the wet pellet used directly for conjugation to folate. b) Conjugation of folate to hydrazine modified PL A nanoparticles A sample of the hydrazine modified PLA nanoparticles (3 μl wet pellet) was suspended in distilled water (250 μl). Aqueous solutions of folate (10 mg/ml, 400 μl) and ED AC (100 mg/ml, 100 μl) were added and the reaction mixture shaken overnight at room temperature. The suspension was spun down and the supernatant removed. The pellet was washed repeatedly with distilled water (6 washes). The residual pellet, which was pale pink in colour, was vacuum dried.
Comparative Examples
Two control reactions were performed concurrently with the above conjugation. In the first a 3 mg sample of hydrazine-modified PLA nanoparticles was treated with the folate as described above but distilled water was used in place of the ED AC solution. In the second control a 2 mg sample of unmodified PLA nanoparticles was treated with both folate and ED AC as described above. For both controls the pellet remaining after repeated washing was a clear white colour with no evidence of any associated folate.
Example 9 Preparation of isobutyl-cyanoacrylate (IBCA) nanocapsules, surface- coated with folate
Nanocapsules suitable for biodistribution studies were prepared with ,25I-insulin as ant internal marker. Briefly, 10 mg insulin was dissolved at lOmg/ml in 0.1 M HC1. An aliquot (Iμl) of ,25I-insulin was added to the cold insulin, which was mixed with lOOμl miglyol and vortexed. EtOH (10 ml ) was added to the insulin/miglyol mix and mixed by vortexing. Isobutyl-cyanoacrylate IBCA (100 μl, Sicomet) was added to the clear solution, which was immediately added to 60 ml 0.25% F-127. After 30 minutes the preparation was split into 2 equal halves. One half was left to stir overnight, whilst to the other half was added 27mg folate-PEG-octadecanoic acid (80 mg/ml in EtOH). The solution was left to stir overnight. Both solutions were then treated in a similar fashion. Large aggregates were removed by centrifugation at 10K rpm for 20 minutes. Both particle preparations were concentrated and washed in a Amicon positive pressure filtration unit using a 300,000 MW cut off membrane. Particles were stabilised by surface cross-linking with di- succinimidyl-2-aminoethyl-2-amino-2-benzyl-ethanoate (DSAB). DSAB was converted to the NHS-ester as follows. DSAB (40 mg) was dissolved in an equal weight of DMF, to which was added NHS (24 mg, 240μl DMF). DCC (Dicyclohexylcarbodiimide, 44mg, 440μl, made up fresh) was then added to the DSAB mixture and allowed to activate for 20 min while stirring rapidly. The DSAB-NHS-ester was added at 0.32 mg per 2.1 mg nanocapsules, and left to stir overnight. The particles were then dialysed before use in biodistribution studies.
Example 10 Demonstration of folate-mediated targeting of nanoparticles.
In order to examine the potential utility of folate as a targeting agent for nanoparticles, folate derivatized IBCA nanoparticles were prepared as described in Example 9. Control nanoparticles were prepared without folate. For biodistribution studies, Balb/C mice were injected subcutaneous, y with 2x106 hybridoma tumour cells. Two weeks after tumour injection, the radio-labelled nanoparticles were injected intravenously into the mice. At various time-points the mice were bled from the retro-orbital plexus, euthanased and their tissues removed for determination of radioactivity. Data is presented in Figure 1 as the percentage of injected counts that were injected in the mice.
A small but lower quantity of uptake of unmodified nanoparticles into the tumour was found as can be seen from Figure 1 , the quantity of nanoparticles targeted to the tumour increased in the presence of surface folate.
Industrial applications
The present invention provides a simple and novel technique for the amplification of the folate uptake system, thus enabling the amplified delivery of a wide range of active agents to tumor and cancer cells in particular.
References
Oppenheim R.C. (1984) in "Polymeric Microparticles" (Guiot, P and Couvreur, P. Eds.) CRC Press, Boca Raton. Oppenheim R.C., Gipps, E.M. Forbes, J.F. and Whitehead R.H. (1984) in "Nanoparticles and Drug Therapy" (Davis, S.S., Ilium, L., McVie, J.G. and Tomlinson, E. Eds) Elsevier Science Publishers B.V.
Oppenheim, R.C, Stewart, N.F., Gordon, L. and Patel, H.M. (1982) Drug Devel. Indust. Pharm. 8: 531-546. Allen, R.H. and Majerus, P.W. (1972) J.Biol. Chem. 247: 7702-7717.
Yamada, R.-H and H.P.C. Hogenkamp. (1972) J.Biol.Chem. 247 : 6266-6270.

Claims

The claims defining the invention are as follows:
1. A complex comprising a nanosphere or nanocapsule, to which is coupled a targeting molecule, said nanosphere or nanocapsule enclosing an active substance, and wherein said targeting molecule is folic acid, or an analogue thereof possessing binding activity to the folic acid receptor.
2. A complex of claim 1 wherein the active substance is a hormone, drug, prodrug, pharmaceutically active protein, immunogen, or DNA or RNA analogue.
3. A complex of claim 2 wherein the active substance is a toxin, cytotoxic agent or prodrug thereof.
4. A complex of claim 3 wherein the toxin is selected from the group consisting of ricin, abrin, diphtheria toxin, modecin, tetanus toxin, mycotoxins, mellitin, α- amanitin, pokeweed antiviral protein, and ribosome inhibiting proteins, especially those of wheat, barley, corn, rye, gelonin, maytansinoid.
5. A complex of claim 3 wherein the cytotoxic agent is selected from the group consisting of chlorambucil, cyclophosphamide, melphalan, cyclopropane, doxorubicin, daunomycin, adriamycin, mitomycin C, [2- (hydroxymethyl)anthraquinone], methotrexate, dichloromethatrexate: cisplatin, carboplatin, metallopeptides containing platinum, copper, vanadium, iron, cobalt, gold, cadmium, zinc and nickel, DON, thymidine, pentamethylmelamin, dianhydrogalactitol, 5-Methyl-THF, anguidine, maytansine, neocarzinostatin, chlorozotocin, AZQ, 2'deoxycoformycin, PALA, AD-32, m-AMSA and misonidazole.
6. A complex of claim 1 wherein the nanosphere or nanoparticle is prepared by solvent evaporation, complex coacervation, polymer/polymer incompatibility, gelation, interfacial polymerisation or thermal denaturation.
7. A complex of claim 6 wherein the nanosphere or nanoparticle is biodegradable.
8. A process for the production of a complex of claim 1, which process comprises one or more of the following steps:
a. reacting nanoparticles with a targeting molecule to form the complex; b. chemically modifying a targeting molecule to provide at least one functional group capable of forming a chemical linkage and reacting nanoparticles and the modified targeting molecules to form the complex; c. reacting nanoparticles with at least one cross-linking agent to prepare "activated" nanoparticles which are reacted with a targeting molecule to form the complex; d. reacting a targeting molecule with at least one cross-linking agent and reacting the nanoparticles with the reacted targeting molecule to form the complex; e. reacting nanoparticles and a targeting molecule with at least one cross- linking agent to the complex; f. reacting nanoparticles with at least one cross-linking agent, reacting a targeting molecule with at least one cross-linking agent and reacting the reacted nanoparticles and the reacted targeting molecule to form the complex; or g. reacting a targeting molecule with at least one cross-linking agent to prepare an analogue which is reacted with a hydrophobic moiety to form a hydrophobic derivative of the targeting molecule, and then incubating the hydrophobic derivative of the targeting molecule with a nanosphere in such a manner that the nanosphere is coated hydrophobically with the targeting molecule.
9. A process of claim 8 wherein the cross-linking agent contains a disulfϊde bond or is cleavable by acid, base or periodate.
10. A process of claim 8 wherein the cross-linking agent is selected from the group consisting of N-(4-azidophenylthio)phthalimide, 4,4'-dithiobisphenylazide, dithiobis(succinimidylpropionate), dimethyl-3,3'-dithiobispropionimidate.2HCl, 3,3' -dithiobis-(sulfosuccinimidylpropionate), ethyl-4-azidophenyl)- 1 ,3 'dithiopropionate, sulfosuccinimidyl-2-(m-azido-o-nitrobenzamido)-ethyl- 1,3'- dithiobutyrimidate.HCl, N-succinimidyl-(4-azidophenyl)- 1 ,3 'dithiopropionate; sulfosuccinimidyl-2-(m-azido-o-nitrobenzamido)-ethyl- 1,3' -dithiopropionate, sulfosuccinimidyl-2-(p-azidosalicylamido)-ethyl- 1,3' -dithiopropionate, N- succinimidyl-3-(2-pyridylthio)propionate, sulfosuccinimidyl-(4- azidophenyldithio)-propionate, 2-iminothiolane, disuccinimidyl tartrate and bis-[2- (succinimidyloxycarbonyloxy)-ethyl]-sulfone.
11. A process of claim 8 wherein the targeting molecule is cross-linked to the nanosphere or nanoparticle by reaction of the carrier with a carbodiimide and N- hydroxysuccinimide (ΝHS), and then reacting the ΝHS derivative with a suitable functional group on the nanosphere.
12. A process of claim 8 wherein the cross-linking agent contains a biodegradable bond
13. A process of claim 12 wherein the cross-linking agent is cleaved by an esterase, glutathione, or azo-reductase.
14. A complex prepared by a process of claim 8.
15. A pharmaceutical composition comprising a complex of claim 1 or claim 14 in association with a pharmaceutically acceptable carrier, excipient, diluent, or adjuvant.
16. A method for the treatment or prophylaxis of disease in a vertebrate host, including a human, which method comprises the administration to said host a therapeutically effective amount of a complex of claim 1 or 14 or a pharmaceutical composition of claim 15.
17. A method of claim 16 wherein the disease is cancer.
18. A method of claim 16 wherein the administration is parenteral administration.
19. A method of claim 16 wherein the administration is oral administration.
20. Use of a nanoparticle complex of claim 1 or claim 14 in the preparation of a medicament for the treatment, prophylaxis or amelioration of disease.
21. Use of claim 20 wherein the disease is cancer.
22. A method of delivering an active substance to a tumor or cancer cell comprising contacting said tumor or cancer cell with a nanoparticle complex comprising a nanoparticle to which is coupled a targeting molecule, said nanoparticle enclosing the active substance, and wherein said targeting molecule is folic acid, or an analogue thereof possessing binding activity for the folic acid receptor.
PCT/AU2000/000405 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using nanoparticles WO2000066090A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000614976A JP2002543110A (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using nanoparticles
CA002372834A CA2372834A1 (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using nanoparticles
AU40942/00A AU4094200A (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using nanoparticles
EP00920285A EP1206251A4 (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using nanoparticles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ0146 1999-05-04
AUPQ0146A AUPQ014699A0 (en) 1999-05-04 1999-05-04 Amplification of folate-mediated targeting to tumor cells using nanoparticles

Publications (1)

Publication Number Publication Date
WO2000066090A1 true WO2000066090A1 (en) 2000-11-09

Family

ID=3814353

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2000/000405 WO2000066090A1 (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using nanoparticles

Country Status (5)

Country Link
EP (1) EP1206251A4 (en)
JP (1) JP2002543110A (en)
AU (2) AUPQ014699A0 (en)
CA (1) CA2372834A1 (en)
WO (1) WO2000066090A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404334A1 (en) * 2001-05-15 2004-04-07 Faulk Pharmaceuticals, Inc. Targeted delivery of bioaffecting compounds for the treatment of cancer
US6780896B2 (en) 2002-12-20 2004-08-24 Kimberly-Clark Worldwide, Inc. Stabilized photoinitiators and applications thereof
JP2005523878A (en) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション Treatment method using ligand / immunogen complex
EP1578450A1 (en) * 2002-11-21 2005-09-28 Access Pharmaceuticals Australia Pty Ltd Amplification of biotin-mediated targeting
WO2009054841A2 (en) * 2007-10-22 2009-04-30 Sensient Flavors Inc. Heat stable microcapsules and methods for making and using the same
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
US7976825B2 (en) * 2007-12-06 2011-07-12 Janos Borbely Cancer cell diagnosis by targeting delivery of nanodevices
US8183208B2 (en) 2001-05-15 2012-05-22 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of viral infections
WO2012061480A3 (en) * 2010-11-02 2013-01-03 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US8409618B2 (en) 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
WO2014121819A1 (en) * 2013-02-06 2014-08-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Folate functionalized nanodiamond particles, method for its preparation and their use
WO2014155146A1 (en) * 2013-03-28 2014-10-02 Bbs Nanotechnology Llc Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
WO2014155144A1 (en) * 2013-03-28 2014-10-02 Bbs Nanotechnology Llc Stable nanocomposition comprising docetaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
WO2014155142A1 (en) * 2013-03-28 2014-10-02 Bbs Nanotechnology Ltd. Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
WO2016172069A1 (en) * 2015-04-20 2016-10-27 Washington State University Methods of treating inflammation associated airway diseases and viral infections
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
US10434185B2 (en) 2017-01-20 2019-10-08 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
US20190374469A1 (en) * 2010-12-02 2019-12-12 Greenmark Biomedical Inc. Aptamer bioconjugate drug delivery device
US11311545B2 (en) 2014-10-09 2022-04-26 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
US11666515B2 (en) 2018-03-28 2023-06-06 Greenmark Biomedical Inc. Phosphate crosslinked starch nanoparticle and dental treatments
US11839623B2 (en) 2018-01-12 2023-12-12 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004277379A (en) * 2003-03-18 2004-10-07 Medicos Hirata:Kk Drug delivery system for inducing apoptosis
US7627296B2 (en) 2004-10-18 2009-12-01 Research In Motion Limited Method of controlling a plurality of internal antennas in a mobile communication device
ATE472560T1 (en) * 2004-11-09 2010-07-15 Basf Se N-SUBSTITUTED IMIDES AS POLYMERIZATION INITIATORS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010038A1 (en) * 1994-09-28 1996-04-04 Apollon, Inc. Multifunctional molecular complexes for gene transfer to cells
WO1997025067A2 (en) * 1996-01-06 1997-07-17 Danbiosyst Uk Limited Polymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5972707A (en) * 1994-06-27 1999-10-26 The Johns Hopkins University Gene delivery system
ES2208923T3 (en) * 1996-07-03 2004-06-16 PHARMACIA & UPJOHN COMPANY WHITE DISTRIBUTION OF MEDICINES WITH THE HELP OF SULFONAMID DERIVATIVES.
WO1998016201A1 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6207195B1 (en) * 1997-06-13 2001-03-27 The Johns Hopkins University Therapeutic nanospheres

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010038A1 (en) * 1994-09-28 1996-04-04 Apollon, Inc. Multifunctional molecular complexes for gene transfer to cells
WO1997025067A2 (en) * 1996-01-06 1997-07-17 Danbiosyst Uk Limited Polymers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GINOBBI P. ET AL.: "Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells", ANTICANCER RESEARCH, vol. 17, 1997, pages 29 - 36 *
See also references of EP1206251A4 *
WEINER E.C. ET AL.: "Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor", INVESTIGATIVE RADIOLOGY, vol. 32, no. 12, December 1997 (1997-12-01), pages 748 - 754 *

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183208B2 (en) 2001-05-15 2012-05-22 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of viral infections
EP1404334A1 (en) * 2001-05-15 2004-04-07 Faulk Pharmaceuticals, Inc. Targeted delivery of bioaffecting compounds for the treatment of cancer
US7001991B2 (en) 2001-05-15 2006-02-21 Faulk Pharmaceuticals, Inc. Targeted delivery of bioaffecting compounds for the treatment of cancer
US7417023B2 (en) 2001-05-15 2008-08-26 Faulk Pharmaceuticals, Inc. Targeted delivery of bioaffecting compounds for the treatment of cancer
EP1404334A4 (en) * 2001-05-15 2005-02-02 Faulk Pharmaceuticals Inc Targeted delivery of bioaffecting compounds for the treatment of cancer
JP2005523878A (en) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション Treatment method using ligand / immunogen complex
EP1578450A4 (en) * 2002-11-21 2009-06-17 Access Pharmaceuticals Austral Amplification of biotin-mediated targeting
EP1578450A1 (en) * 2002-11-21 2005-09-28 Access Pharmaceuticals Australia Pty Ltd Amplification of biotin-mediated targeting
US8409618B2 (en) 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
US6780896B2 (en) 2002-12-20 2004-08-24 Kimberly-Clark Worldwide, Inc. Stabilized photoinitiators and applications thereof
WO2009054841A3 (en) * 2007-10-22 2009-11-05 Sensient Flavors Inc. Heat stable microcapsules and methods for making and using the same
WO2009054841A2 (en) * 2007-10-22 2009-04-30 Sensient Flavors Inc. Heat stable microcapsules and methods for making and using the same
US7976825B2 (en) * 2007-12-06 2011-07-12 Janos Borbely Cancer cell diagnosis by targeting delivery of nanodevices
WO2012061480A3 (en) * 2010-11-02 2013-01-03 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
EP2635260A2 (en) * 2010-11-02 2013-09-11 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
EP2635260A4 (en) * 2010-11-02 2014-07-09 Univ Nebraska Compositions and methods for the delivery of therapeutics
AU2011323458B2 (en) * 2010-11-02 2017-02-23 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US11369570B2 (en) 2010-12-02 2022-06-28 Greenmark Biomedical Inc. Aptamer bioconjugate drug delivery device
US20210338585A1 (en) * 2010-12-02 2021-11-04 Greenmark Biomedical Inc. Aptamer bioconjugate drug delivery device
US20190374469A1 (en) * 2010-12-02 2019-12-12 Greenmark Biomedical Inc. Aptamer bioconjugate drug delivery device
US9173950B2 (en) 2012-05-17 2015-11-03 Extend Biosciences, Inc. Vitamin D-ghrelin conjugates
US9289507B2 (en) 2012-05-17 2016-03-22 Extend Biosciences, Inc. Carriers for improved drug delivery
US9884124B2 (en) 2012-05-17 2018-02-06 Extend Biosciences, Inc. Carriers for improved drug delivery
WO2014121819A1 (en) * 2013-02-06 2014-08-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Folate functionalized nanodiamond particles, method for its preparation and their use
US9283285B2 (en) 2013-03-28 2016-03-15 Bbs Nanotechnology Ltd. Stable nanocomposition comprising docetaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
WO2014155146A1 (en) * 2013-03-28 2014-10-02 Bbs Nanotechnology Llc Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
WO2014155142A1 (en) * 2013-03-28 2014-10-02 Bbs Nanotechnology Ltd. Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
WO2014155144A1 (en) * 2013-03-28 2014-10-02 Bbs Nanotechnology Llc Stable nanocomposition comprising docetaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US11311545B2 (en) 2014-10-09 2022-04-26 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US11116816B2 (en) 2014-10-22 2021-09-14 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US10406202B2 (en) 2014-10-22 2019-09-10 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US10420819B2 (en) 2014-10-22 2019-09-24 Extend Biosciences, Inc. Insulin vitamin D conjugates
US10702574B2 (en) 2014-10-22 2020-07-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016172069A1 (en) * 2015-04-20 2016-10-27 Washington State University Methods of treating inflammation associated airway diseases and viral infections
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
US10576161B2 (en) 2017-01-20 2020-03-03 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
US10434185B2 (en) 2017-01-20 2019-10-08 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
US11839623B2 (en) 2018-01-12 2023-12-12 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
US11666515B2 (en) 2018-03-28 2023-06-06 Greenmark Biomedical Inc. Phosphate crosslinked starch nanoparticle and dental treatments
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof

Also Published As

Publication number Publication date
CA2372834A1 (en) 2000-11-09
EP1206251A4 (en) 2004-06-30
EP1206251A1 (en) 2002-05-22
AU4094200A (en) 2000-11-17
AUPQ014699A0 (en) 1999-05-27
JP2002543110A (en) 2002-12-17

Similar Documents

Publication Publication Date Title
WO2000066090A1 (en) Amplification of folate-mediated targeting to tumor cells using nanoparticles
EP0531497B1 (en) Oral delivery systems for microparticles
US20060127310A1 (en) Amplification of biotin-mediated targeting
US6221397B1 (en) Surface cross-linked particles suitable for controlled delivery
Zhong et al. Targeting drug delivery system for platinum (Ⅳ)-Based antitumor complexes
Chen et al. Recent advances in epsilon-poly-L-lysine and L-lysine-based dendrimer synthesis, modification, and biomedical applications
Cai et al. Reduction-and pH-sensitive hyaluronan nanoparticles for delivery of iridium (III) anticancer drugs
JP4813712B2 (en) Drug-carrier complex and method of using the same
JP2011524446A (en) Chitosan oligosaccharide fatty acid graft product modified with polyglycol, its preparation method and use thereof
CA2376175A1 (en) Vitamin directed dual targeting therapy
JP2014518862A (en) Polymer nanoparticles for drug delivery
MXPA05000766A (en) Gastrointestinal delivery of genetic material coupled to a transporting agent.
AU2004201276A1 (en) Amplification of folate-mediated targeting to tumor cells using nanoparticles
CN109666087B (en) Cyclodextrin derivative and preparation method and application thereof
AU707085B2 (en) Oral delivery systems for microparticles
CN114053248B (en) Nucleic acid and small molecule drug co-delivery nano-preparation for regulating tumor metabolism and preparation method thereof
Steiert Dynamic Protein-based Nanoparticles for Drug Delivery Applications
Maiti Ligand-decorated polysaccharide nanocarriers for targeting therapeutics to hepatocytes
Hüppe Multicomponent encapsulation into protein nanocarriers for co-delivery of therapeutics
CA3225745A1 (en) Targeted glycosaminoglycan-particles and methods of use
KR20230096590A (en) PD-L1 targeting nanoparticle, composition for preventing or treating cancer comprising the same, and manufacturing method thereof
MAHOR et al. International Journal of Pharmacy and Pharmaceutical Sciences
NZ517802A (en) Surface cross-linked particles suitable for controlled delivery in pharmaceutical use
AU8995198A (en) Cross-linked particles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2372834

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2372834

Ref document number: 2000 614976

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000920285

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000920285

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000920285

Country of ref document: EP